Avita has got intellectual property portfolio for its regenerative technology platform
Singapore: Australia based Avita Medical, a regenerative medicine company specializing in the treatment of wounds and skin defects, has recieved US patent for its method of making and using an epithelial cell suspension, an autologous skin regeneration therapy platform (ReCell).
"This newly issued patent continues to strengthen and expand our overall patent coverage for ReCell. Moving forward, we are continuing to focus on the prosecution of additional patents that support our entire regenerative medicine franchise. This patent is a key milestone towards our commercialisation effort in the US" commented Mr Adam Kelliher, CEO, Avita Medical.
The patent provides protection for methods for producing and using a transplantable cellular suspension of living tissue suitable for grafting to a patient. Avita has got intellectual property portfolio for its regenerative technology platform.
ReCell, ReGenerCell and ReNovaCell are protected by a family of patents and patent applications covering unique composition of final product, method of production, device and automation for methods and apparatus to generate epithelial suspension.
